Therefore, it has emerged as a potential therapeutic target for ALS: a persistent altered TGF-β system might promote disease progression by inducing an imbalance of neurogenesis and neurodegeneration. The gene discussed is TGFB1; the disease is amyotrophic lateral sclerosis.